COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #30 of 230
5/7 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Konig et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217690 (Letter)
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19
Source   PDF   Share   Tweet
Analysis of 80 SLE patients diagnosed with COVID-19, showing the frequency of hospitalisation did not differ between individuals using an antimalarial versus non-users (55% (16/29) vs 57% (29/51), p=ns. Authors suggest that the dosage used may be too low to reach therapeutic levels.

Konig et al., 5/7/2020, retrospective, database analysis, multiple countries, multiple regions, preprint, 11 authors.
risk of hospitalization, 3.0% lower, RR 0.97, p = 0.88, treatment 16 of 29 (55.2%), control 29 of 51 (56.9%).
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.